| Name | Title | Contact Details |
|---|
Bioclinica is the leader in scientifically-driven services and technology-enabled solutions in clinical research. Clinical trials are complex, and traditional approaches are either monolithic or fragmented. Successful trials require an ability to see key details and uncover hidden insights. Employing our scientifically-driven and technology-enabled approach, Bioclinica brings CLARITY to clinical trials for better decisions. With such clarity comes the insight to help trial sponsors and Clinical Research Organizations (CROs) develop new life-improving therapies more efficiently and safely ─ and with improved quality outcomes. Our scientific, medical, technology and domain expertise is unmatched and spans all major therapeutic areas ─ and the full trial lifecycle, from study protocol, to post-approval. Key offerings include: Medical imaging; Cardiac Safety; Clinical Adjudication; Randomization & Trial Supply Management and Optimization; Electronic and eSource Data Capture; Site Payments and Forecasting; Pharmacovigilance; Trial Management; and Risk-based Monitoring. Additionally, as a true multifaceted partner to trial sponsors and CROs, Bioclinica offers an integrated App xChange partner ecosystem, a global Research Network of investigative sites, Patient Recruitment and Lost to Follow-up Services, and Post-approval Research expertise. Bioclinica and our thousands of employees serve more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 biopharmaceutical companies and leading CROs – through a network of offices in the U.S., Europe, and Asia.
Health Risk Management, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Touchstone Health Partnership is a White Plains, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Metamark Genetics, Inc. is a privately held biotechnology company founded in 2007 to develop novel, function-based, prognostic and diagnostic tests aimed at improving cancer care. The company's proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, colon, and breast cancers. In early 2014, Metamark plans to commercialize ProMark™—its prostate cancer prognostic test—through its Cambridge, Massachusetts CLIA-certified laboratory. For more information, please visit the company's Website at www.metamarkgenetics.com. Metamark™ and ProMark™ are trademarks of Metamark Genetics, Inc.
Wellteq is creating the future of precision wellness through a digital wellbeing ecosystem taking users from point of prevention through to point of care. Delivered into the corporate health and insurance sector to drive user engagement through a personalised wellness journey. wellteq uses a range of data types from wearable devices, sensors, biomarkers and user-generated data that, in combination with machine learning and artificial intelligence enables individual-level insights into Stress, Fatigue, Sleep Quality, Cognitive Function and Activity levels. Behavioural science and content targeting use biometric and behavioural analytics to deliver personalised wellness insights and practical recommendations to build engagement, agency and more effective sustainable management of personal wellness. Programs are highly customisable and provide an experience packed with gamification, group projects, social interaction rewards and charity all to maximise healthy behavioural change. With customisation comes flexibility, which is paramount for businesses of all shapes and sizes around the world today.